Overview

Generic Name(s):
ixabepilone
Trade Name(s):
Ixempra
NCI Definition [1]:
An orally bioavailable semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines.

Ixabepilone has been investigated in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials investigating ixabepilone, 3 are phase 2 (2 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for ixabepilone clinical trials.

Breast carcinoma, fallopian tube carcinoma, and ovarian carcinoma are the most common diseases being investigated in ixabepilone clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ixabepilone
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Ixabepilone
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ixabepilone and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Ixempra, ixabepilone (product), ixabepilone (substance), bms-247550, epothilone, epothilone-b bms 247550, ixabepilone, azaepothilone b, bms 247550, 219989-84-1, epothilone b lactam, (1s,3s,7s,10r,11s,12s,16r)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1e)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione, ixabepilone, ixabepilone [chemical/ingredient], aza-epothilone b, 710428, bms247550, ixempra
Drug Categories [2]:
Antimicrotubule agents
NCIT ID [1]:
C37452
SNOMED ID [1]:
C-9002E

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.